Financial Information

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397

Inside Stayble: February 2021

25 February 2021

In the February 2021 edition, CEO Andreas Gerward, discusses the oversubscribed rights issue, next steps and partnering activities.

Inside Stayble is a communication channel aiming to provide shareholders with monthly updates about Stayble Therapeutics and its clinical development program for STA363 in chronic low back pain.

Stayble Therapeutics is listed on Nasdaq First North in Sweden (STABL).

Read more at staybletherapeutics.com

Back

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397